<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37605276</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>28</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1750-1326</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Aug</Month><Day>21</Day></PubDate></JournalIssue><Title>Molecular neurodegeneration</Title><ISOAbbreviation>Mol Neurodegener</ISOAbbreviation></Journal><ArticleTitle>TDP-43-regulated cryptic RNAs accumulate in Alzheimer's disease brains.</ArticleTitle><Pagination><StartPage>57</StartPage><MedlinePgn>57</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">57</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13024-023-00646-z</ELocationID><Abstract><AbstractText Label="BACKGROUND">Inclusions of TAR DNA-binding protein 43&#xa0;kDa (TDP-43) has been designated limbic-predominant, age-related TDP-43 encephalopathy (LATE), with or without co-occurrence of Alzheimer's disease (AD). Approximately, 30-70% AD cases present TDP-43 proteinopathy (AD-TDP), and a greater disease severity compared to AD patients without TDP-43 pathology. However, it remains unclear to what extent TDP-43 dysfunction is involved in AD pathogenesis.</AbstractText><AbstractText Label="METHODS">To investigate whether TDP-43 dysfunction is a prominent feature in AD-TDP cases, we evaluated whether non-conserved cryptic exons, which serve as a marker of TDP-43 dysfunction in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD-TDP), accumulate in AD-TDP brains. We assessed a cohort of 192 post-mortem brains from three different brain regions: amygdala, hippocampus, and frontal cortex. Following RNA and protein extraction, qRT-PCR and immunoassays were performed to quantify the accumulation of cryptic RNA targets and phosphorylated TDP-43 pathology, respectively.</AbstractText><AbstractText Label="RESULTS">We detected the accumulation of misspliced cryptic or skiptic RNAs of STMN2, KCNQ2, UNC13A, CAMK2B, and SYT7 in the amygdala and hippocampus of AD-TDP cases. The topographic distribution of cryptic RNA accumulation mimicked that of phosphorylated TDP-43, regardless of TDP-43 subtype classification. Further, cryptic RNAs efficiently discriminated AD-TDP cases from controls.</AbstractText><AbstractText Label="CONCLUSIONS">Overall, our results indicate that cryptic RNAs may represent an intriguing new therapeutic and diagnostic target in AD, and that methods aimed at detecting and measuring these species in patient biofluids could be used as a reliable tool to assess TDP-43 pathology in AD. Our work also raises the possibility that TDP-43 dysfunction and related changes in cryptic splicing could represent a common molecular mechanism shared between AD-TDP and FTLD-TDP.</AbstractText><CopyrightInformation>&#xa9; 2023. Editorial Group and BioMed Central Ltd., part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Estades Ayuso</LastName><ForeName>Virginia</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pickles</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Todd</LastName><ForeName>Tiffany</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yue</LastName><ForeName>Mei</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jansen-West</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Yuping</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonz&#xe1;lez Bejarano</LastName><ForeName>Jes&#xfa;s</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rawlinson</LastName><ForeName>Bailey</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeTure</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill R</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boeve</LastName><ForeName>Bradley F</ForeName><Initials>BF</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knopman</LastName><ForeName>David S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Josephs</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrucelli</LastName><ForeName>Leonard</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prudencio</LastName><ForeName>Mercedes</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-4894-4858</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA. prudencio.mercedes@mayo.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, Jacksonville, FL, USA. prudencio.mercedes@mayo.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Research, Neuroscience, Mayo Clinic College of Medicine, 4500 San Pablo Rd, Jacksonville, FL, 32224, USA. prudencio.mercedes@mayo.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U19 AG063911</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062677</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG037491</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS084974</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35 NS097273</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 NS120992</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 NS123743</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Neurodegener</MedlineTA><NlmUniqueID>101266600</NlmUniqueID><ISSNLinking>1750-1326</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="Y">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Cryptic RNA</Keyword><Keyword MajorTopicYN="N">LATE</Keyword><Keyword MajorTopicYN="N">STMN2</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword></KeywordList><CoiStatement>BFB receives institutional research grant support from Alector, Biogen, Transposon, Cognition Therapeutics, and GE Healthcare. BFB receives honorarium for SAB activities for the Tau Consortium. LP is a consultant for Expansion Therapeutics. DSK serves on a Data Safety Monitoring Board for the Dominantly Inherited Alzheimer Network Treatment Unit study. DSK served on a Data Safety monitoring Board for a tau therapeutic for Biogen (until 2021) but received no personal compensation. DSK is an investigator in clinical trials sponsored by Biogen, Lilly Pharmaceuticals, and the University of Southern California. DSK has served as a consultant for Roche, Samus Therapeutics, Magellan Health, Biovie and Alzeca Biosciences but receives no personal compensation. DSK attended an Eisai advisory board meeting for lecanemab on December 2, 2022, but received no compensation. DSK receives funding from the NIH. All other authors declare no disclosures or conflicts of interest related to the content of the article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>22</Day><Hour>0</Hour><Minute>27</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37605276</ArticleId><ArticleId IdType="pmc">PMC10441763</ArticleId><ArticleId IdType="doi">10.1186/s13024-023-00646-z</ArticleId><ArticleId IdType="pii">10.1186/s13024-023-00646-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer&#x2019;s disease. Mol neurodegeneration. 2019;14(1):1&#x2013;18. doi: 10.1186/s13024-019-0333-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-019-0333-5</ArticleId><ArticleId IdType="pmc">PMC6679484</ArticleId><ArticleId IdType="pubmed">31375134</ArticleId></ArticleIdList></Reference><Reference><Citation>Amador-Ortiz C, Lin WL, Ahmed Z, Personett D, Davies P, Duara R, et al. TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer&#x2019;s disease. Ann Neurol. 2007;61(5):435&#x2013;45. doi: 10.1002/ana.21154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21154</ArticleId><ArticleId IdType="pmc">PMC2677204</ArticleId><ArticleId IdType="pubmed">17469117</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, Mackenzie IR, Hasegawa M, Nonoka T, Niizato K, Tsuchiya K, et al. Phosphorylated TDP-43 in Alzheimer&#x2019;s disease and dementia with Lewy bodies. Acta Neuropathol. 2009;117(2):125&#x2013;36. doi: 10.1007/s00401-008-0480-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-008-0480-1</ArticleId><ArticleId IdType="pubmed">19139911</ArticleId></ArticleIdList></Reference><Reference><Citation>Higashi S, Iseki E, Yamamoto R, Minegishi M, Hino H, Fujisawa K, et al. Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer&#x2019;s disease and dementia with Lewy bodies. Brain Res. 2007;1184:284&#x2013;94. doi: 10.1016/j.brainres.2007.09.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2007.09.048</ArticleId><ArticleId IdType="pubmed">17963732</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu WT, Josephs KA, Knopman DS, Boeve BF, Dickson DW, Petersen RC, et al. Temporal lobar predominance of TDP-43 neuronal cytoplasmic inclusions in Alzheimer disease. Acta Neuropathol. 2008;116(2):215&#x2013;20. doi: 10.1007/s00401-008-0400-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-008-0400-4</ArticleId><ArticleId IdType="pmc">PMC3404722</ArticleId><ArticleId IdType="pubmed">18592255</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadokura A, Yamazaki T, Lemere CA, Takatama M, Okamoto K. Regional distribution of TDP-43 inclusions in Alzheimer disease (AD) brains: their relation to AD common pathology. Neuropathology: official journal of the Japanese Society of Neuropathology. 2009;29(5):566&#x2013;73. doi: 10.1111/j.1440-1789.2009.01017.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1789.2009.01017.x</ArticleId><ArticleId IdType="pubmed">19422539</ArticleId></ArticleIdList></Reference><Reference><Citation>Uryu K, Nakashima-Yasuda H, Forman MS, Kwong LK, Clark CM, Grossman M, et al. Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J Neuropathol Exp Neurol. 2008;67(6):555&#x2013;64. doi: 10.1097/NEN.0b013e31817713b5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e31817713b5</ArticleId><ArticleId IdType="pmc">PMC3659339</ArticleId><ArticleId IdType="pubmed">18520774</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Dickson DW, Tosakulwong N, Weigand SD, Murray ME, Petrucelli L, et al. Rates of hippocampal atrophy and presence of post-mortem TDP-43 in patients with Alzheimer&#x2019;s disease: a longitudinal retrospective study. Lancet Neurol. 2017;16(11):917&#x2013;24. doi: 10.1016/S1474-4422(17)30284-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30284-3</ArticleId><ArticleId IdType="pmc">PMC5646369</ArticleId><ArticleId IdType="pubmed">28919059</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson JL, Porta S, Garrett FG, Zhang P, Xie SX, Suh E, et al. Limbic-predominant age-related TDP-43 encephalopathy differs from frontotemporal lobar degeneration. Brain. 2020;143(9):2844&#x2013;57. doi: 10.1093/brain/awaa219.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa219</ArticleId><ArticleId IdType="pmc">PMC7526723</ArticleId><ArticleId IdType="pubmed">32830216</ArticleId></ArticleIdList></Reference><Reference><Citation>Besser LM, Teylan MA, Nelson PT. Limbic predominant age-related TDP-43 Encephalopathy (LATE): Clinical and Neuropathological Associations. J Neuropathol Exp Neurol. 2020;79(3):305&#x2013;13. doi: 10.1093/jnen/nlz126.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/nlz126</ArticleId><ArticleId IdType="pmc">PMC7036651</ArticleId><ArticleId IdType="pubmed">31845964</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Dickson DW, Trojanowski JQ, Jack CR, Boyle PA, Arfanakis K, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain. 2019;142(6):1503&#x2013;27. doi: 10.1093/brain/awz099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz099</ArticleId><ArticleId IdType="pmc">PMC6536849</ArticleId><ArticleId IdType="pubmed">31039256</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006;351(3):602&#x2013;11. doi: 10.1016/j.bbrc.2006.10.093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2006.10.093</ArticleId><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130&#x2013;3. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Bejanin A, Murray ME, Martin P, Botha H, Tosakulwong N, Schwarz CG, et al. Antemortem volume loss mirrors TDP-43 staging in older adults with non-frontotemporal lobar degeneration. Brain. 2019;142(11):3621&#x2013;35. doi: 10.1093/brain/awz277.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz277</ArticleId><ArticleId IdType="pmc">PMC6821218</ArticleId><ArticleId IdType="pubmed">31562527</ArticleId></ArticleIdList></Reference><Reference><Citation>Wennberg AM, Whitwell JL, Tosakulwong N, Weigand SD, Murray ME, Machulda MM, et al. The influence of tau, amyloid, alpha-synuclein, TDP-43, and vascular pathology in clinically normal elderly individuals. Neurobiol Aging. 2019;77:26&#x2013;36. doi: 10.1016/j.neurobiolaging.2019.01.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2019.01.008</ArticleId><ArticleId IdType="pmc">PMC6486870</ArticleId><ArticleId IdType="pubmed">30776649</ArticleId></ArticleIdList></Reference><Reference><Citation>Buciuc M, Botha H, Murray ME, Schwarz CG, Senjem ML, Jones DT et al. Utility of FDG-PET in diagnosis of Alzheimer-related TDP-43-proteinopathy. Neurology. 2020:In press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7371379</ArticleId><ArticleId IdType="pubmed">32518145</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling SC, Polymenidou M, Cleveland DW. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron. 2013;79(3):416&#x2013;38. doi: 10.1016/j.neuron.2013.07.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.07.033</ArticleId><ArticleId IdType="pmc">PMC4411085</ArticleId><ArticleId IdType="pubmed">23931993</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymenidou M, Lagier-Tourenne C, Hutt KR, Huelga SC, Moran J, Liang TY, et al. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat Neurosci. 2011;14(4):459&#x2013;68. doi: 10.1038/nn.2779.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2779</ArticleId><ArticleId IdType="pmc">PMC3094729</ArticleId><ArticleId IdType="pubmed">21358643</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling JP, Pletnikova O, Troncoso JC, Wong PC. TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD. Science. 2015;349(6248):650&#x2013;5. doi: 10.1126/science.aab0983.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aab0983</ArticleId><ArticleId IdType="pmc">PMC4825810</ArticleId><ArticleId IdType="pubmed">26250685</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatanpaa KJ, Bigio EH, Cairns NJ, Womack KB, Weintraub S, Morris JC, et al. TAR DNA-binding protein 43 immunohistochemistry reveals extensive neuritic pathology in FTLD-U: a midwest-southwest consortium for FTLD study. J Neuropathol Exp Neurol. 2008;67(4):271&#x2013;9. doi: 10.1097/NEN.0b013e31816a12a6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e31816a12a6</ArticleId><ArticleId IdType="pmc">PMC2635119</ArticleId><ArticleId IdType="pubmed">18379440</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Murray ME, Whitwell JL, Parisi JE, Petrucelli L, Jack CR, et al. Staging TDP-43 pathology in Alzheimer&#x2019;s disease. Acta Neuropathol. 2014;127(3):441&#x2013;50. doi: 10.1007/s00401-013-1211-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1211-9</ArticleId><ArticleId IdType="pmc">PMC3944799</ArticleId><ArticleId IdType="pubmed">24240737</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan RH, Kril JJ, Fatima M, McGeachie A, McCann H, Shepherd C, et al. TDP-43 proteinopathies: pathological identification of brain regions differentiating clinical phenotypes. Brain. 2015;138(Pt 10):3110&#x2013;22. doi: 10.1093/brain/awv220.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awv220</ArticleId><ArticleId IdType="pubmed">26231953</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Murray ME, Whitwell JL, Tosakulwong N, Weigand SD, Petrucelli L, et al. Updated TDP-43 in Alzheimer&#x2019;s disease staging scheme. Acta Neuropathol. 2016;131(4):571&#x2013;85. doi: 10.1007/s00401-016-1537-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1537-1</ArticleId><ArticleId IdType="pmc">PMC5946692</ArticleId><ArticleId IdType="pubmed">26810071</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Del Tredici K, Irwin DJ, Grossman M, Robinson JL, Toledo JB, et al. Sequential distribution of pTDP-43 pathology in behavioral variant frontotemporal dementia (bvFTD) Acta Neuropathol. 2014;127(3):423&#x2013;39. doi: 10.1007/s00401-013-1238-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1238-y</ArticleId><ArticleId IdType="pmc">PMC3971993</ArticleId><ArticleId IdType="pubmed">24407427</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Murray ME, Tosakulwong N, Weigand SD, Serie AM, Perkerson RB, et al. Pathological, imaging and genetic characteristics support the existence of distinct TDP-43 types in non-FTLD brains. Acta Neuropathol. 2019;137(2):227&#x2013;38. doi: 10.1007/s00401-018-1951-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1951-7</ArticleId><ArticleId IdType="pmc">PMC6358471</ArticleId><ArticleId IdType="pubmed">30604226</ArticleId></ArticleIdList></Reference><Reference><Citation>Tom&#xe9; SO, Vandenberghe R, Ospitalieri S, Van Schoor E, Tousseyn T, Otto M, et al. Distinct molecular patterns of TDP-43 pathology in Alzheimer&#x2019;s disease: relationship with clinical phenotypes. Acta Neuropathol Commun. 2020;8(1):61. doi: 10.1186/s40478-020-00934-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-020-00934-5</ArticleId><ArticleId IdType="pmc">PMC7189555</ArticleId><ArticleId IdType="pubmed">32349792</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong YH, Ling JP, Lin SZ, Donde AN, Braunstein KE, Majounie E, et al. Tdp-43 cryptic exons are highly variable between cell types. Mol Neurodegener. 2017;12(1):13. doi: 10.1186/s13024-016-0144-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-016-0144-x</ArticleId><ArticleId IdType="pmc">PMC5289002</ArticleId><ArticleId IdType="pubmed">28153034</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun M, Bell W, LaClair KD, Ling JP, Han H, Kageyama Y, et al. Cryptic exon incorporation occurs in Alzheimer&#x2019;s brain lacking TDP-43 inclusion but exhibiting nuclear clearance of TDP-43. Acta Neuropathol. 2017;133(6):923&#x2013;31. doi: 10.1007/s00401-017-1701-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1701-2</ArticleId><ArticleId IdType="pmc">PMC5444385</ArticleId><ArticleId IdType="pubmed">28332094</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma XR, Prudencio M, Koike Y, Vatsavayai SC, Kim G, Harbinski F, et al. TDP-43 represses cryptic exon inclusion in the FTD-ALS gene UNC13A. Nature. 2022;603(7899):124&#x2013;30. doi: 10.1038/s41586-022-04424-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04424-7</ArticleId><ArticleId IdType="pmc">PMC8891019</ArticleId><ArticleId IdType="pubmed">35197626</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown AL, Wilkins OG, Keuss MJ, Hill SE, Zanovello M, Lee WC, et al. TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A. Nature. 2022;603(7899):131&#x2013;7. doi: 10.1038/s41586-022-04436-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04436-3</ArticleId><ArticleId IdType="pmc">PMC8891020</ArticleId><ArticleId IdType="pubmed">35197628</ArticleId></ArticleIdList></Reference><Reference><Citation>Melamed Z, Lopez-Erauskin J, Baughn MW, Zhang O, Drenner K, Sun Y, et al. Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nat Neurosci. 2019;22(2):180&#x2013;90. doi: 10.1038/s41593-018-0293-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0293-z</ArticleId><ArticleId IdType="pmc">PMC6348009</ArticleId><ArticleId IdType="pubmed">30643298</ArticleId></ArticleIdList></Reference><Reference><Citation>Klim JR, Williams LA, Limone F, Guerra San Juan I, Davis-Dusenbery BN, Mordes DA, et al. ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair. Nat Neurosci. 2019;22(2):167&#x2013;79. doi: 10.1038/s41593-018-0300-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0300-4</ArticleId><ArticleId IdType="pmc">PMC7153761</ArticleId><ArticleId IdType="pubmed">30643292</ArticleId></ArticleIdList></Reference><Reference><Citation>Humphrey J, Emmett W, Fratta P, Isaacs AM, Plagnol V. Quantitative analysis of cryptic splicing associated with TDP-43 depletion. BMC Med Genomics. 2017;10(1):38. doi: 10.1186/s12920-017-0274-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12920-017-0274-1</ArticleId><ArticleId IdType="pmc">PMC5446763</ArticleId><ArticleId IdType="pubmed">28549443</ArticleId></ArticleIdList></Reference><Reference><Citation>Seddighi S, Qi YA, Brown AL, Wilkins OG, Bereda C, Belair C et al. Mis-spliced transcripts generate de novo proteins in TDP-43-related ALS/FTD. bioRxiv. 2023.</Citation></Reference><Reference><Citation>Prudencio M, Humphrey J, Pickles S, Brown AL, Hill SE, Kachergus JM et al. Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia. J Clin Invest. 2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7598060</ArticleId><ArticleId IdType="pubmed">32790644</ArticleId></ArticleIdList></Reference><Reference><Citation>Krus KL, Strickland A, Yamada Y, Devault L, Schmidt RE, Bloom AJ, et al. Loss of Stathmin-2, a hallmark of TDP-43-associated ALS, causes motor neuropathy. Cell Rep. 2022;39(13):111001. doi: 10.1016/j.celrep.2022.111001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2022.111001</ArticleId><ArticleId IdType="pmc">PMC9327139</ArticleId><ArticleId IdType="pubmed">35767949</ArticleId></ArticleIdList></Reference><Reference><Citation>Graf ER, Heerssen HM, Wright CM, Davis GW, DiAntonio A. Stathmin is required for stability of the Drosophila neuromuscular junction. J Neurosci. 2011;31(42):15026&#x2013;34. doi: 10.1523/JNEUROSCI.2024-11.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2024-11.2011</ArticleId><ArticleId IdType="pmc">PMC3207242</ArticleId><ArticleId IdType="pubmed">22016536</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerra San Juan I, Nash LA, Smith KS, Leyton-Jaimes MF, Qian M, Klim JR, et al. Loss of mouse Stmn2 function causes motor neuropathy. Neuron. 2022;110(10):1671&#x2013;88. doi: 10.1016/j.neuron.2022.02.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2022.02.011</ArticleId><ArticleId IdType="pmc">PMC9119928</ArticleId><ArticleId IdType="pubmed">35294901</ArticleId></ArticleIdList></Reference><Reference><Citation>Duncan JE, Lytle NK, Zuniga A, Goldstein LS. The Microtubule Regulatory protein stathmin is required to maintain the Integrity of Axonal Microtubules in Drosophila. PLoS ONE. 2013;8(6):e68324. doi: 10.1371/journal.pone.0068324.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0068324</ArticleId><ArticleId IdType="pmc">PMC3694009</ArticleId><ArticleId IdType="pubmed">23840848</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin KE, Jasin P, Braunstein KE, Sinha I, Bowden KD, Moghekar A et al. A fluid biomarker reveals loss of TDP-43 splicing repression in pre-symptomatic ALS. bioRxiv. 2023.</Citation></Reference><Reference><Citation>Pickles S, Gendron TF, Koike Y, Yue M, Song Y, Kachergus JM, et al. Evidence of cerebellar TDP-43 loss of function in FTLD-TDP. Acta Neuropathol Commun. 2022;10(1):107. doi: 10.1186/s40478-022-01408-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-022-01408-6</ArticleId><ArticleId IdType="pmc">PMC9310392</ArticleId><ArticleId IdType="pubmed">35879741</ArticleId></ArticleIdList></Reference><Reference><Citation>Baughn MW, Melamed Z, Lopez-Erauskin J, Beccari MS, Ling K, Zuberi A, et al. Mechanism of STMN2 cryptic splice-polyadenylation and its correction for TDP-43 proteinopathies. Science. 2023;379(6637):1140&#x2013;9. doi: 10.1126/science.abq5622.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abq5622</ArticleId><ArticleId IdType="pmc">PMC10148063</ArticleId><ArticleId IdType="pubmed">36927019</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239&#x2013;59. doi: 10.1007/BF00308809.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00308809</ArticleId><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray ME, Graff-Radford NR, Ross OA, Petersen RC, Duara R, Dickson DW. Neuropathologically defined subtypes of Alzheimer&#x2019;s disease with distinct clinical characteristics: a retrospective study. Lancet Neurol. 2011;10(9):785&#x2013;96. doi: 10.1016/S1474-4422(11)70156-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(11)70156-9</ArticleId><ArticleId IdType="pmc">PMC3175379</ArticleId><ArticleId IdType="pubmed">21802369</ArticleId></ArticleIdList></Reference><Reference><Citation>Prudencio M, Gonzales PK, Cook CN, Gendron TF, Daughrity LM, Song Y, et al. Repetitive element transcripts are elevated in the brain of C9orf72 ALS/FTLD patients. Hum Mol Genet. 2017;26(17):3421&#x2013;31. doi: 10.1093/hmg/ddx233.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddx233</ArticleId><ArticleId IdType="pmc">PMC5886204</ArticleId><ArticleId IdType="pubmed">28637276</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Del Tredici K, Toledo JB, Robinson JL, Irwin DJ, Grossman M, et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol. 2013;74(1):20&#x2013;38. doi: 10.1002/ana.23937.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.23937</ArticleId><ArticleId IdType="pmc">PMC3785076</ArticleId><ArticleId IdType="pubmed">23686809</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EB, Porta S, Michael Baer G, Xu Y, Suh E, Kwong LK, et al. Expansion of the classification of FTLD-TDP: distinct pathology associated with rapidly progressive frontotemporal degeneration. Acta Neuropathol. 2017;134(1):65&#x2013;78. doi: 10.1007/s00401-017-1679-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1679-9</ArticleId><ArticleId IdType="pmc">PMC5521959</ArticleId><ArticleId IdType="pubmed">28130640</ArticleId></ArticleIdList></Reference><Reference><Citation>Nana AL, Sidhu M, Gaus SE, Hwang JL, Li L, Park Y, et al. Neurons selectively targeted in frontotemporal dementia reveal early stage TDP-43 pathobiology. Acta Neuropathol. 2019;137(1):27&#x2013;46. doi: 10.1007/s00401-018-1942-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1942-8</ArticleId><ArticleId IdType="pmc">PMC6339592</ArticleId><ArticleId IdType="pubmed">30511086</ArticleId></ArticleIdList></Reference><Reference><Citation>LaClair KD, Donde A, Ling JP, Jeong YH, Chhabra R, Martin LJ, et al. Depletion of TDP-43 decreases fibril and plaque beta-amyloid and exacerbates neurodegeneration in an Alzheimer&#x2019;s mouse model. Acta Neuropathol. 2016;132(6):859&#x2013;73. doi: 10.1007/s00401-016-1637-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1637-y</ArticleId><ArticleId IdType="pmc">PMC5131701</ArticleId><ArticleId IdType="pubmed">27785573</ArticleId></ArticleIdList></Reference><Reference><Citation>Bieche I, Maucuer A, Laurendeau I, Lachkar S, Spano AJ, Frankfurter A, et al. Expression of stathmin family genes in human tissues: non-neural-restricted expression for SCLIP. Genomics. 2003;81(4):400&#x2013;10. doi: 10.1016/S0888-7543(03)00031-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0888-7543(03)00031-4</ArticleId><ArticleId IdType="pubmed">12676564</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin JE, Geisler S, DiAntonio A. Dynamic regulation of SCG10 in regenerating axons after injury. Exp Neurol. 2014;252:1&#x2013;11. doi: 10.1016/j.expneurol.2013.11.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2013.11.007</ArticleId><ArticleId IdType="pmc">PMC3947015</ArticleId><ArticleId IdType="pubmed">24246279</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin JE, Miller BR, Babetto E, Cho Y, Sasaki Y, Qayum S, et al. SCG10 is a JNK target in the axonal degeneration pathway. Proc Natl Acad Sci U S A. 2012;109(52):E3696&#x2013;705. doi: 10.1073/pnas.1216204109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1216204109</ArticleId><ArticleId IdType="pmc">PMC3535671</ArticleId><ArticleId IdType="pubmed">23188802</ArticleId></ArticleIdList></Reference><Reference><Citation>Morii H, Shiraishi-Yamaguchi Y, Mori N. SCG10, a microtubule destabilizing factor, stimulates the neurite outgrowth by modulating microtubule dynamics in rat hippocampal primary cultured neurons. J Neurobiol. 2006;66(10):1101&#x2013;14. doi: 10.1002/neu.20295.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/neu.20295</ArticleId><ArticleId IdType="pubmed">16838365</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin LW, Masliah E, Iimoto D, Deteresa R, Mallory M, Sundsmo M, et al. Neurofibrillary tangle-associated alteration of stathmin in Alzheimer&#x2019;s disease. Neurobiol Aging. 1996;17(3):331&#x2013;41. doi: 10.1016/0197-4580(96)00021-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-4580(96)00021-8</ArticleId><ArticleId IdType="pubmed">8725893</ArticleId></ArticleIdList></Reference><Reference><Citation>Okazaki T, Wang H, Masliah E, Cao M, Johnson SA, Sundsmo M, et al. SCG10, a neuron-specific growth-associated protein in Alzheimer&#x2019;s disease. Neurobiol Aging. 1995;16(6):883&#x2013;94. doi: 10.1016/0197-4580(95)02001-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-4580(95)02001-2</ArticleId><ArticleId IdType="pubmed">8622778</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es MA, Veldink JH, Saris CG, Blauw HM, van Vught PW, Birve A, et al. Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat Genet. 2009;41(10):1083&#x2013;7. doi: 10.1038/ng.442.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.442</ArticleId><ArticleId IdType="pubmed">19734901</ArticleId></ArticleIdList></Reference><Reference><Citation>Diekstra FP, van Vught PW, van Rheenen W, Koppers M, Pasterkamp RJ, van Es MA, et al. UNC13A is a modifier of survival in amyotrophic lateral sclerosis. Neurobiol Aging. 2012;33(3):630e3&#x2013;8. doi: 10.1016/j.neurobiolaging.2011.10.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2011.10.029</ArticleId><ArticleId IdType="pubmed">22118904</ArticleId></ArticleIdList></Reference><Reference><Citation>Koike Y, Pickles S, Estades Ayuso V, Jansen-West K, Qi YA, Li Z, et al. TDP-43 and other hnRNPs regulate cryptic exon inclusion of a key ALS/FTD risk gene, UNC13A. PLoS Biol. 2023;21(3):e3002028. doi: 10.1371/journal.pbio.3002028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.3002028</ArticleId><ArticleId IdType="pmc">PMC10057836</ArticleId><ArticleId IdType="pubmed">36930682</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartlage-Rubsamen M, Waniek A, Rossner S. Munc13 genotype regulates secretory amyloid precursor protein processing via postsynaptic glutamate receptors. Int J Dev Neurosci. 2013;31(1):36&#x2013;45. doi: 10.1016/j.ijdevneu.2012.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijdevneu.2012.10.001</ArticleId><ArticleId IdType="pubmed">23070049</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossner S, Fuchsbrunner K, Lange-Dohna C, Hartlage-Rubsamen M, Bigl V, Betz A, et al. Munc13-1-mediated vesicle priming contributes to secretory amyloid precursor protein processing. J Biol Chem. 2004;279(27):27841&#x2013;4. doi: 10.1074/jbc.C400122200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.C400122200</ArticleId><ArticleId IdType="pubmed">15123597</ArticleId></ArticleIdList></Reference><Reference><Citation>Barthet G, Jorda-Siquier T, Rumi-Masante J, Bernadou F, Muller U, Mulle C. Presenilin-mediated cleavage of APP regulates synaptotagmin-7 and presynaptic plasticity. Nat Commun. 2018;9(1):4780. doi: 10.1038/s41467-018-06813-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-06813-x</ArticleId><ArticleId IdType="pmc">PMC6235831</ArticleId><ArticleId IdType="pubmed">30429473</ArticleId></ArticleIdList></Reference><Reference><Citation>Habif M, Do Carmo S, Baez MV, Colettis NC, Cercato MC, Salas DA, et al. Early long-term memory impairment and changes in the expression of synaptic Plasticity-Associated genes, in the McGill-R-Thy1-APP rat model of Alzheimer&#x2019;s-Like Brain Amyloidosis. Front Aging Neurosci. 2020;12:585873. doi: 10.3389/fnagi.2020.585873.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2020.585873</ArticleId><ArticleId IdType="pmc">PMC7862771</ArticleId><ArticleId IdType="pubmed">33551786</ArticleId></ArticleIdList></Reference><Reference><Citation>Surti TS, Jan LY. A potassium channel, the M-channel, as a therapeutic target. Curr Opin Investig Drugs. 2005;6(7):704&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">16044666</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonham LW, Evans DS, Liu Y, Cummings SR, Yaffe K, Yokoyama JS. Neurotransmitter pathway genes in cognitive decline during aging: evidence for GNG4 and KCNQ2 genes. Am J Alzheimers Dis Other Demen. 2018;33(3):153&#x2013;65. doi: 10.1177/1533317517739384.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1533317517739384</ArticleId><ArticleId IdType="pmc">PMC6209098</ArticleId><ArticleId IdType="pubmed">29338302</ArticleId></ArticleIdList></Reference><Reference><Citation>Song MK, Cui YY, Zhang WW, Zhu L, Lu Y, Chen HZ. The facilitating effect of systemic administration of Kv7/M channel blocker XE991 on LTP induction in the hippocampal CA1 area independent of muscarinic activation. Neurosci Lett. 2009;461(1):25&#x2013;9. doi: 10.1016/j.neulet.2009.05.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2009.05.042</ArticleId><ArticleId IdType="pubmed">19463897</ArticleId></ArticleIdList></Reference><Reference><Citation>Duran-Gonzalez J, Michi ED, Elorza B, Perez-Cordova MG, Pacheco-Otalora LF, Touhami A, et al. Amyloid beta peptides modify the expression of antioxidant repair enzymes and a potassium channel in the septohippocampal system. Neurobiol Aging. 2013;34(8):2071&#x2013;6. doi: 10.1016/j.neurobiolaging.2013.02.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.02.005</ArticleId><ArticleId IdType="pmc">PMC4890633</ArticleId><ArticleId IdType="pubmed">23473707</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayordomo-Cava J, Yajeya J, Navarro-Lopez JD, Jimenez-Diaz L. Amyloid-beta(25&#x2013;35) modulates the expression of GirK and KCNQ Channel genes in the Hippocampus. PLoS ONE. 2015;10(7):e0134385. doi: 10.1371/journal.pone.0134385.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0134385</ArticleId><ArticleId IdType="pmc">PMC4517786</ArticleId><ArticleId IdType="pubmed">26218288</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>